全文获取类型
收费全文 | 46951篇 |
免费 | 3410篇 |
国内免费 | 770篇 |
专业分类
耳鼻咽喉 | 373篇 |
儿科学 | 500篇 |
妇产科学 | 594篇 |
基础医学 | 5929篇 |
口腔科学 | 473篇 |
临床医学 | 4847篇 |
内科学 | 2826篇 |
皮肤病学 | 117篇 |
神经病学 | 637篇 |
特种医学 | 3264篇 |
外国民族医学 | 1篇 |
外科学 | 9658篇 |
综合类 | 6163篇 |
现状与发展 | 2篇 |
一般理论 | 1篇 |
预防医学 | 1867篇 |
眼科学 | 524篇 |
药学 | 2412篇 |
23篇 | |
中国医学 | 501篇 |
肿瘤学 | 10419篇 |
出版年
2024年 | 74篇 |
2023年 | 514篇 |
2022年 | 1346篇 |
2021年 | 1682篇 |
2020年 | 1621篇 |
2019年 | 1261篇 |
2018年 | 1456篇 |
2017年 | 1498篇 |
2016年 | 1508篇 |
2015年 | 1588篇 |
2014年 | 3359篇 |
2013年 | 3058篇 |
2012年 | 2839篇 |
2011年 | 3128篇 |
2010年 | 2495篇 |
2009年 | 2731篇 |
2008年 | 2806篇 |
2007年 | 2781篇 |
2006年 | 2301篇 |
2005年 | 1910篇 |
2004年 | 1585篇 |
2003年 | 1320篇 |
2002年 | 1073篇 |
2001年 | 966篇 |
2000年 | 830篇 |
1999年 | 727篇 |
1998年 | 654篇 |
1997年 | 622篇 |
1996年 | 420篇 |
1995年 | 419篇 |
1994年 | 397篇 |
1993年 | 277篇 |
1992年 | 240篇 |
1991年 | 206篇 |
1990年 | 182篇 |
1989年 | 182篇 |
1988年 | 165篇 |
1987年 | 135篇 |
1986年 | 97篇 |
1985年 | 140篇 |
1984年 | 89篇 |
1983年 | 64篇 |
1982年 | 78篇 |
1981年 | 79篇 |
1980年 | 67篇 |
1979年 | 51篇 |
1978年 | 34篇 |
1977年 | 31篇 |
1976年 | 19篇 |
1975年 | 11篇 |
排序方式: 共有10000条查询结果,搜索用时 14 毫秒
11.
《Journal of the American College of Radiology》2020,17(3):384-390
PurposeEffective written communication directly affects health care outcomes. Since 2016, the complex language of state-mandated breast density notifications (BDNs) has been challenged, because it is perceived to be beyond the comprehension of most patients. The aim of this study was to assess whether a revised BDN written at a lower reading grade level improves understanding compared with the current state-mandated BDN.MethodsA revised notification with similar content to the current state-mandated BDN was developed. Both notifications were presented to patients for direct comparison, using a paper survey asking questions that evaluated patients’ perceptions and convictions associated with breast density. Surveys were distributed at four outpatient imaging centers to screening mammography patients.ResultsThe current BDN’s mean readability metric was 13.4, and that of the revised BDN was 6.6. Five hundred surveys were analyzed. Survey data demonstrated that 56.6% of all women perceived that dense breast tissue results indicated a “high” associated lifetime breast cancer risk from the current state-mandated BDN compared with only 2.2% with the revised notification (P < .001). Nearly all women were more likely to initiate discussions with their providers regarding their breast tissue density after reading the revised notification (96.0%) as opposed to the current state-mandated BDN (32.8%; P < .001).ConclusionsA significant portion of women misinterpret the intended messages of the current state-mandated BDN. Thus, a revised notification at a lower reading grade level may improve understanding of breast density, leading to improved individualized breast cancer screening for women with dense breasts. 相似文献
12.
13.
《Radiologia》2022,64(3):256-265
Breast cancer is the second most common cancer in Peruvian women. Due to limitations in national breast cancer screening programs, especially in rural areas, more than 50% of cases of breast cancer in Peru are diagnosed in advanced stages. In collaboration with a local clinic registered as a nongovernmental organization (CerviCusco), RAD-AID International aims to create a sustainable diagnostic structure to improve breast cancer screening in Cuzco. With the support of local, national, and international partners that have collaborated in analyzing radiological resources, raising awareness in the population, acquiring equipment, training clinical staff, and building referral networks, our teams of radiologists, included in the RAD-AID team, have participated in training CerviCusco staff in breast ultrasound, thus enabling additional training for radiology residents through a regulated international collaboration. 相似文献
14.
Mark Verrill 《Surgery (Oxford)》2019,37(3):181-185
Multimodality primary therapies for breast cancer combined with earlier detection have led to a sharp decline in the death rate from breast cancer in the UK over the last 40 years in the face of a rising incidence. The latest UK statistics from Cancer Research UK report 55,122 new cases of breast cancer in 2015 with 11,563 deaths from breast cancer recorded in 2016. Crudely, this equates to a cure rate of around 80% for all comers and demonstrates a clear improvement in outcome with 50,285 new cases in 2011 and 11,716 deaths in 2012. Despite this good news, there are still significant numbers of women (and men) who suffer from either a local recurrence or metastatic disease following apparently successful treatment for early breast cancer (Stage I to III). Only a minority of individuals, 6.6% with the stage recorded at diagnosis, present with stage IV disease. This review considers the treatment options available to individuals with locally recurrent and advanced breast cancer (ABC). 相似文献
15.
HER2-positive (HER2+) breast cancer (BC) is a heterogenous and multifaceted disease, with interesting therapeutic implications. First, all intrinsic molecular subtypes can be identified in HER2+ tumors, with the HER2-enriched being the most frequent. Such subtypes do not differ much from their counterparts in HER2-negative disease, apart for the high expression of genes in/near the HER2 amplicon on chromosome 17. Intrinsic subtyping, along with the quantification of ERBB2 mRNA levels, is associated with higher rates of pathologic complete response across neoadjuvant trials of dual HER2 blockade and might help select patients for de-escalation and escalation treatment strategies. Secondly, HER2+ tumors have a broad range of DNA alterations. ERBB2 mutations and alterations in the PI3K/Akt/mTOR pathway are among the most frequent and might predict benefit from potent pan-HER, PI3K and mTOR inhibitors. Moreover, HER2+ tumors are usually infiltrated by lymphocytes. These tumor infiltrating-lymphocytes (TILs) predict response to neoadjuvant anti-HER2-based treatment and exert a prognostic role. PD-L1, detected in ∼42 % of HER2+ BC, might also be useful to define patients responding to novel anti-PD1/PD-L1 immunotherapies. New multiparametric clinicopathologic and genomic tools accounting for this complexity, such as HER2DX, are under development to define more tailored treatment approaches. Finally, HER2-targeted antibody-drug conjugates (ADC) such as trastuzumab deruxtecan might be active in tumors with low expression of HER2. Overall, there is a need to molecularly characterize and develop novel targeted therapies for HER2+ disease. 相似文献
16.
17.
BackgroundPrior reports demonstrate the expression of estrogen and progesterone receptors in high-grade gliomas (HGGs), but the relationship between hormone receptor-positive disease and risk of HHGs in patients with breast cancer (BC) remains uncharacterized.MethodsUsing the SEER 18 registries (2000–2017), we examined the temporal trend of the incidence of HGGs and BC. The standardized incidence ratio was calculated to assess the risk of subsequent HGG in BC patients.ResultsDuring the study period, the incidence of BC and HGGs remained comparable for men and women. Among 976,134 patients with BC, we found a decreased incidence of HGGs in females, but not in males. Female BC patients with hormone receptor-positive disease were at a lower risk of developing glioblastoma and anaplastic astrocytoma.ConclusionOur study findings allude to the protective role of hormone exposure in the development of HGGs, which may lead to the development of therapies targeting hormonal pathways. 相似文献
18.
19.
20.
《Clinical breast cancer》2022,22(7):629-633
Metastatic HER2-positive (HER2+) and triple-negative breast cancer (TNBC) confer a 30% or higher risk of developing brain metastases (BrM), but BrM is typically an exclusion criteria for clinical trials, which limits the generalizability of trial results to these patients. We therefore analysed trends in the enrollment of patients with BrM, as well as the use of outcomes specific to the central nervous system (CNS), in phase III clinical trials evaluating systemic therapy for patients with advanced HER2+ and/or TNBC. Notably, 10 of the 34 trials (29%, 95% confidence interval = 15.1%-47.5%) evaluated CNS-specific outcomes and trials that completely excluded patients with BrM were significantly less likely to meet their primary endpoint (n = 6/17, 35%) than those that permitted conditional enrollment (n = 13/15, 87%) (P = .005), suggesting that enrollment of patients with BrM is not detrimental to trial success. 相似文献